Why Is MONTE ROSA THERAPEUT (GLUE) Stock Down Today?
By the Top Tier Newswire AI Desk · October 2, 2026 at 1:42 PM ET · reviewed against 8 wire stories
MONTE ROSA THERAPEUT (GLUE) is down -5.86% in the latest session. Our newswire has captured 8 stories on GLUE across 7 sources in the last 36 hours, with AI sentiment reading bullish (avg 65/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why GLUE stock is down today
Monte Rosa Therapeutics (GLUE) fell 5.86% to $10.60 in afternoon trading on October 2, 2026. The stock opened higher but reversed course after a wave of selling pressure emerged in the afternoon. Despite positive Phase 1 results for its lead candidate MRT-8102, the stock has struggled to maintain momentum following a sharp pre-market rally earlier in the week.
What Happened
Monte Rosa announced strong Phase 1 data for MRT-8102, a NEK7-directed molecular glue degrader, showing 80%, 90% NEK7 degradation and broad reductions in inflammatory markers. The GFORCE-1 study reported normalization of key pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) in subjects with elevated CVD risk. These findings were disclosed in a Form 8-K filing and covered in detail by multiple outlets including MarketWatch, Business Insider, and GlobeNewswire. H.C. Wainwright initiated coverage on the stock with a Buy rating and a $25 price target. However, the stock's sharp intraday reversal suggests investor skepticism or profit-taking after a 20% pre-market surge.
What The Data Shows
The stock opened at $11.24 and reached an intraday high of $11.40 at 9:30 AM ET before declining to a low of $10.59 at 1:35 PM ET. Trading volume of 0.7 million shares was 50% above the 3-month daily average. The stock closed at $10.61, down from its opening price. Over the last eight sessions, GLUE has declined 1.6% from $12.21 to $12.01. In the last 90 days, insiders have sold a total of $462,000 worth of shares, with the most recent transaction on July 17. The stock has hit 19 fresh 52-week lows on October 2.
What To Watch
Monte Rosa has no upcoming earnings date scheduled. Investors should monitor the breadth of analyst coverage and any follow-up data from the GFORCE-1 trial.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
GLUE · today's session (5-min) · -5.49% vs prior close · updated 5:46 PM ETAI sentiment, last 36h · averaged over 8 stories · 65/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
1d agoSeeking AlphaBULLISH 56Product/PR
Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript
Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk October 1,...
1d agoSeeking AlphaBULLISH 67Product/PR
Monte Rosa plans mid-stage trials for anti-inflammatory agent after positive Phase 1 data
Monte Rosa Therapeutics (GLUE) stock gains as the company plans Phase 2 trials for anti-inflammatory agent MRT-8102 after strong Phase 1 results. Read more here.
1d agoMarketWatchBULLISH 67Product/PR
Monte Rosa Therapeutics Sees Positive Trial Results for Cardiovascular Disease Treatment
Monte Rosa’s MRT-8102 Phase 1 data show 80%–90% NEK7 degradation and broad inflammatory marker reductions
October 1, 2026
Monte Rosa Therapeutics (GLUE) reported positive Phase 1 GFORCE-1 data for MRT-8102, citing robust and sustained NEK7 degradation of approximately 80%–90% across tested doses and broad reductions in ASCVD-related biomarkers. The company also reported a favorable safety profile with no serious adverse events and TEAE rates similar to placebo, and outlined planned Phase 2 studies in coronary artery disease, gout, and hidradenitis suppurativa.
1d agoGlobeNewswireBULLISH 73Product/PR
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized multiple atherosclerotic...
1d agoBusiness InsiderBULLISH 73Product/PR
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized multiple atherosclerotic...
1d agoThe FlyBULLISH 61Analyst
Monte Rosa Therapeutics initiated with a Buy at H.C. Wainwright
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →